JPH0347246B2 - - Google Patents
Info
- Publication number
- JPH0347246B2 JPH0347246B2 JP57020266A JP2026682A JPH0347246B2 JP H0347246 B2 JPH0347246 B2 JP H0347246B2 JP 57020266 A JP57020266 A JP 57020266A JP 2026682 A JP2026682 A JP 2026682A JP H0347246 B2 JPH0347246 B2 JP H0347246B2
- Authority
- JP
- Japan
- Prior art keywords
- gelatin
- aqueous solution
- acid
- hpmc
- acetate succinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Description
本発明は腸溶性基剤特にヒドロキシプロピルメ
チルセルロースアセテートサクシネートの水溶液
から腸溶性カプセルを製造する方法に関するもの
である。
腸溶性カプセルは医薬品を封入し服用される
が、従来、このようなカプセルの製造方法として
はゼラチン製のカプセルを腸溶性高分子物質で被
覆する方法、腸溶性高分子物質の有機溶媒溶液に
成型ピンを浸漬し成形する方法、およびゼラチン
とセルロースアセテートフタレートあるいはヒド
ロキシプロピルメチルセルロースフタレートのア
ルカリ金属塩の水溶液に成型ピンを浸漬し成形す
る方法等が知られている。
しかしながら、ゼラチン製のカプセルを腸溶性
高分子物質で被覆する方法には、ゼラチンの表面
と被覆膜との接着不良が生じ易く、有機溶媒溶液
を使用する方法では溶媒の回収工程、作業環境汚
染、火災爆発対策が必要で、しかも成品への溶媒
の残留が懸念される。また前記ゼラチンとセルロ
ースアセテートフタレートあるいはヒドロキシプ
ロピルメチルセルロースフタレートのアルカリ金
属塩の水溶液を使用する場合には加水分解を起こ
したり、カプセルがもろい等の問題点がある。
本発明者らは前記欠点を解消し、化学的に安定
で耐衝撃性にすぐれたカプセルを製造する方法を
種々検討した結果、ヒドロキシプロピルメチルセ
ルロースアセテートサクシネートのアルカリ金属
塩とゼラチンを含む水溶液に成型ピンを浸漬し成
型した後、酸水溶液に浸漬処理することにより、
きわめてすぐれた腸溶性カプセルを得ることがで
きることを見出し、本発明を完成した。
以下本発明を詳細に説明する。
本発明に用いられるヒドロキシプロピルメチル
セルロースアセテートサクシネート(HPMC−
AS)は、他の腸溶性基剤とは異なつてそれ自体
が非常に柔軟性に富んだ基剤であるため、ゼラチ
ンと併用する場合に、腸溶性基剤に対するゼラチ
ンの添加の割合を下げてももろくならず、強度の
すぐれたカプセルを製造することができ、またゼ
ラチンの添加の割合が下がることにより、胃液お
よび水に対する安定性が向上するため腸に到達す
るまでに破壊される懸念がなく、すぐれた腸溶性
の機能を発揮することができる。また、他の基剤
では柔軟性を付与するためには多量の可塑剤の添
加を必要とするが、本発明の方法では可塑剤の添
加は全く必要としないかないしは少量の添加でよ
いため、可塑剤がにじみ出す等の障害を起こすこ
とがない。
本発明の方法に使用されるHPMC−ASはすで
に知られたものであり、例えば酢酸またはプロピ
オン酸等のカルボン酸を反応媒体として使用し、
酢酸ナトリウム、酢酸カリウム等のカルボン酸の
アルカリ金属塩触媒の存在下に、ヒドロキシプロ
ピルメチルセルロースと無水酢酸および無水コハ
ク酸とをエステル化反応させる方法、あるいはこ
のエステル化反応をアセトン等の適当な溶媒中で
ピリジン等の塩基性触媒の存在下で行わせる方法
等により製造することができる。本発明の目的に
おいてはこのHPMC−ASとしてグルコース単位
1個あたりの置換基の平均置換数がヒドロキシプ
ロポキシル基0.1〜0.8、メトキシル基1.4〜1.9、
アセチル基0.2〜0.8、酸性サクシノイル基0.1〜
0.7であるものが好適とされる。
ゼラチンはその水溶液(浸漬液)に成型ピンを
浸漬し引上げたときに、浸漬液が流れてカプセル
の肉厚が不均一なものとなるのを防止するための
ものであり、その効果を発揮させるためには浸漬
液から成型ピンを引上げた後速かに20℃以下に冷
却することが望ましく、またゼラチンの添加量
は、もし少なすぎるとその効果がなく、また多す
ぎると腸溶性の機能が阻害されるほか乾燥後カプ
セルがもろくなるので、HPMC−ASの1重量部
に対して0.05〜0.5重量部の範囲とすることが望
ましい。
水溶液(浸漬液)を調製する方法は特に規制さ
れるものではないが、HPMC−ASの溶解を速や
かに行うためには、まずHPMC−ASを水に分散
したのちかくはんしながら塩基の水溶液を添加す
るとよい。この目的に用いられる塩基としては水
酸化ナトリウム、水酸化カリウム、炭酸水素ナト
リウム、炭酸水素カリウム、炭酸ナトリウム、炭
酸カリウムなどが例示される。これら塩基の使用
量はHPMC−ASの酸性サクシノイル基の当量の
60%以上の当量が適当である。塩基の使用量がこ
の60%よりも少ないとHPMC−ASの水への溶解
が十分に行われないおそれが生じ、カプセルの表
面があれることが懸念される。また溶解をより速
やかに行う目的で該当量で100%を越える過剰を
用いてもさしつかえないが、この場合には
HPMC−AS中のエステル結合が加水分解される
のを防ぐために、これを酸で中和することにより
過剰のアルカリによる弊害をなくするか、あるい
は浸漬液調製後速やかにカプセルを製造すること
が望ましい。
ゼラチンの溶解は、上記のHPMC−ASの溶液
にゼラチンを加えてかくはんしながら加熱溶解す
る、あるいはHPMC−ASの溶液に別に溶解した
ゼラチン水溶液を加熱かくはんしながら混合すれ
ばよく、これによりピン成型用浸漬液としての
HPMC−ASとゼラチンを主体とする水溶液が得
られる。
カプセルの成型は、流動パラフイン、カルナウ
バワツクスなどの離型剤を塗布した成型ピンを上
記のようにして作つた浸漬液に浸漬し、引上げ、
冷却したのちあるいはさらに予備乾燥したのち、
これを酸水溶液中に浸漬して酸処理を施こし、つ
いで乾燥したのちピンから成型体をはずし切断等
の必要な後工程を施こすことにより行われる。
なお、浸漬後の冷却温度は浸漬液が流れてカプ
セルの肉厚が不均一となるのを防止するために20
℃以下望ましくは18℃以下とすることが望まし
い。また上記酸処理は必須の工程であつてこの処
理を施こさないと、HPMC−ASのアルカリ金属
塩は水溶性であるため、服用してから胃に到達す
るまでにカプセルが破壊され、腸溶性の機能が失
われる懸念があるが、酸処理を施こすことにより
HPMC−ASのアルカリ金属塩が水に不溶の遊離
の状態にもどるために、耐水性が得られ、十分に
その機能を発揮することができる。この目的のた
めに使用される酸としては、塩酸、硫酸、硝酸、
りん酸などの無機酸類、酢酸、プロピオン酸、安
息香酸などのモノカルボン酸類、シユウ酸、マロ
ン酸、コハク酸、アジピン酸、マレイン酸、フマ
ル酸、リンゴ酸、酒石酸などの多価カルボン酸が
例示される。
上記酸は水溶液として用いられ、その濃度は酸
の種類によつて異なるが通常3〜30%の範囲が用
いられる。なお、鉱酸類を用いた場合には処理条
件によつてはカプセルに鉱酸類が残存し、
HPMC−ASの分解・変質を起こすことがあるの
で、このような場合には酸処理の後で洗浄するこ
とが望ましい。
カプセルの肉厚は浸漬液中におけるHPMC−
ASおよびゼラチンの濃度、および温度によつて
決定されるが、一般には濃度15〜40重量%、浸漬
温度25〜40℃とすることが望ましい。肉薄のカプ
セルを得ることが目的の場合には低濃度の浸漬液
を、また肉厚のカプセルを得ることが目的の場合
には高濃度の浸漬液をそれぞれ使用することが望
ましい。
なお、浸漬液には必要に応じて着色剤、きよう
味剤、可塑剤、充てん剤などの各種添加剤を配合
することはさしつかえない。
つぎに具体的実施例をあげる。
実施例 1
グルコース単位1個あたりの平均置換数が、ヒ
ドロキシプロポキシル基0.24、メトキシル基
1.87、アセチル基0.44、サクシノイル基0.24であ
るHPMC−ASの200gを水920gにかくはんしな
がら加え、よく分散させてから、10%水酸化ナト
リウム水溶液78gを徐々に添加してHPMC−AS
の水溶液を得た。これにゼラチン25gを添加した
後50℃に昇温し、3時間かくはんして浸漬液を調
整した。この浸漬液を30℃に保ち、離型剤として
カルナウバワツクスを塗布したステンレス製成型
ピンを浸漬して引きあげ乾燥した後、ピンから成
型体をはずし、必要な後工程を施こしカプセルを
得た。
また別途、成型ピンを浸漬引きあげ、室温で約
1時間風乾した後15℃の10%塩酸水溶液に5分間
浸漬した後、20秒間水に浸漬し水洗したものおよ
び10%クエン酸水溶液に5分間浸漬したものを乾
燥し上記と同様の操作によりカプセルを得た。
こうして得たカプセルに乳糖粉末を充てんし、
ボデイとキヤツプのかん合部を上記HPMC−AS
の20%アセトン溶液でシールしたものについて、
日本薬局方第10改正に基づく第1液(PH1.2)、第
2液(PH6.8)および水道水中での変化の様子を
観察したところ、次の表に示すとおりの結果が得
られた。
The present invention relates to a process for preparing enteric capsules from an aqueous solution of an enteric base, particularly hydroxypropyl methyl cellulose acetate succinate. Enteric-coated capsules are used to enclose pharmaceuticals and are ingested. Conventionally, such capsules have been manufactured by coating gelatin capsules with enteric-coated polymeric substances, or by molding enteric-coated polymeric substances into an organic solvent solution. A method in which a pin is immersed and molded, and a method in which a molded pin is immersed in an aqueous solution of an alkali metal salt of gelatin and cellulose acetate phthalate or hydroxypropyl methyl cellulose phthalate and molded are known. However, the method of coating gelatin capsules with an enteric polymer substance tends to cause poor adhesion between the surface of the gelatin and the coating film, and the method of using an organic solvent solution does not contaminate the work environment during the solvent recovery process. , fire and explosion countermeasures are required, and there are concerns about solvent remaining in the product. Furthermore, when an aqueous solution of gelatin and an alkali metal salt of cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate is used, there are problems such as hydrolysis and brittle capsules. The present inventors investigated various methods of manufacturing capsules that are chemically stable and have excellent impact resistance by solving the above-mentioned drawbacks, and as a result, they were molded into an aqueous solution containing an alkali metal salt of hydroxypropyl methylcellulose acetate succinate and gelatin. After immersing the pin and molding it, by immersing it in an acid aqueous solution,
The inventors have discovered that it is possible to obtain extremely excellent enteric-coated capsules, and have completed the present invention. The present invention will be explained in detail below. Hydroxypropyl methyl cellulose acetate succinate (HPMC-
Unlike other enteric-coated bases, AS) is itself a very flexible base, so when used in combination with gelatin, the ratio of gelatin to enteric-coated base must be reduced. It is possible to produce capsules with excellent strength without becoming brittle, and by reducing the proportion of gelatin added, stability against gastric juices and water is improved, so there is no fear that the capsules will be destroyed before reaching the intestines. , can exhibit excellent enteric properties. In addition, while other bases require the addition of a large amount of plasticizer to impart flexibility, the method of the present invention does not require the addition of plasticizer at all or only requires the addition of a small amount. , there will be no problems such as plasticizer oozing out. The HPMC-AS used in the method of the invention is already known, for example by using a carboxylic acid such as acetic acid or propionic acid as the reaction medium;
A method of esterifying hydroxypropyl methylcellulose with acetic anhydride and succinic anhydride in the presence of an alkali metal salt catalyst of a carboxylic acid such as sodium acetate or potassium acetate, or a method of carrying out the esterification reaction in a suitable solvent such as acetone. It can be produced by a method in which it is carried out in the presence of a basic catalyst such as pyridine. For the purpose of the present invention, this HPMC-AS has an average number of substituents per glucose unit of 0.1 to 0.8 hydroxypropoxyl groups, 1.4 to 1.9 methoxyl groups,
Acetyl group 0.2~0.8, acidic succinoyl group 0.1~
A value of 0.7 is preferred. Gelatin is used to prevent the capsule from becoming uneven in thickness due to the dipping liquid flowing when the molding pin is immersed in the aqueous solution (immersion liquid) and pulled up. In order to achieve this, it is desirable to quickly cool the molding pin to below 20°C after pulling it out of the immersion liquid. Also, if the amount of gelatin added is too small, it will not be effective, and if it is too large, the enteric function will be impaired. In addition to being inhibited, the capsule becomes brittle after drying, so it is desirable that the amount be in the range of 0.05 to 0.5 parts by weight per 1 part by weight of HPMC-AS. The method of preparing an aqueous solution (immersion solution) is not particularly regulated, but in order to quickly dissolve HPMC-AS, first disperse HPMC-AS in water and then add an aqueous base solution while stirring. It's good to do that. Examples of bases used for this purpose include sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, and potassium carbonate. The amount of these bases used is equivalent to the acidic succinoyl group of HPMC-AS.
An equivalent weight of 60% or more is suitable. If the amount of base used is less than 60%, there is a risk that HPMC-AS will not be sufficiently dissolved in water, and there is a concern that the surface of the capsule may become rough. It is also possible to use an excess of more than 100% for the purpose of dissolving more quickly, but in this case,
In order to prevent the ester bonds in HPMC-AS from being hydrolyzed, it is desirable to neutralize them with acid to eliminate the harmful effects of excess alkali, or to manufacture capsules immediately after preparing the immersion liquid. . To dissolve gelatin, add gelatin to the above HPMC-AS solution and heat and dissolve while stirring, or mix gelatin aqueous solution separately dissolved in HPMC-AS solution while heating and stirring. This allows pin forming. As an immersion liquid
An aqueous solution consisting mainly of HPMC-AS and gelatin is obtained. To mold the capsule, a molding pin coated with a mold release agent such as liquid paraffin or carnauba wax is immersed in the dipping liquid made as described above, pulled up,
After cooling or further pre-drying,
This is carried out by immersing this in an acid aqueous solution to perform an acid treatment, then drying it, removing the molded body from the pin, and performing necessary post-processes such as cutting. The cooling temperature after immersion is set at 20°C to prevent the immersion liquid from flowing and making the capsule wall thickness uneven.
℃ or less, preferably 18℃ or less. In addition, the acid treatment mentioned above is an essential step, and if this treatment is not performed, the alkali metal salt of HPMC-AS is water-soluble, so the capsule will be destroyed before it reaches the stomach after ingestion, and enteric-coated There is a concern that the function of the product will be lost, but by acid treatment
Since the alkali metal salt of HPMC-AS returns to a free state that is insoluble in water, water resistance can be obtained and its functions can be fully demonstrated. Acids used for this purpose include hydrochloric acid, sulfuric acid, nitric acid,
Examples include inorganic acids such as phosphoric acid, monocarboxylic acids such as acetic acid, propionic acid, benzoic acid, and polyhydric carboxylic acids such as oxalic acid, malonic acid, succinic acid, adipic acid, maleic acid, fumaric acid, malic acid, and tartaric acid. be done. The above acid is used as an aqueous solution, and its concentration varies depending on the type of acid, but is usually in the range of 3 to 30%. Note that when mineral acids are used, mineral acids may remain in the capsule depending on the processing conditions.
Since decomposition and deterioration of HPMC-AS may occur, in such cases it is desirable to wash after acid treatment. The wall thickness of the capsule is HPMC− in the immersion liquid.
Although determined by the concentration of AS and gelatin and temperature, it is generally desirable to have a concentration of 15 to 40% by weight and a dipping temperature of 25 to 40°C. When the purpose is to obtain thin-walled capsules, it is desirable to use a low-concentration immersion liquid, and when the purpose is to obtain thick-walled capsules, it is desirable to use a high-concentration immersion liquid. Note that various additives such as colorants, flavoring agents, plasticizers, and fillers may be added to the immersion liquid as necessary. Next, specific examples will be given. Example 1 The average number of substitutions per glucose unit was 0.24 hydroxypropoxyl groups and 0.24 methoxyl groups.
1.87, an acetyl group of 0.44, and a succinoyl group of 0.24, 200 g of HPMC-AS was added to 920 g of water with stirring, and after being well dispersed, 78 g of a 10% aqueous sodium hydroxide solution was gradually added to form HPMC-AS.
An aqueous solution of was obtained. After adding 25 g of gelatin to this, the temperature was raised to 50°C and stirred for 3 hours to prepare an immersion liquid. This dipping solution is kept at 30°C, and a stainless steel molding pin coated with carnauba wax as a mold release agent is dipped in the liquid, pulled up and dried.The molded body is removed from the pin and subjected to the necessary post-processing to form capsules. Obtained. Separately, a molded pin was immersed, pulled out, air-dried for about an hour at room temperature, immersed in 10% hydrochloric acid aqueous solution at 15°C for 5 minutes, immersed in water for 20 seconds, rinsed with water, and immersed in 10% citric acid aqueous solution for 5 minutes. The dried product was dried and capsules were obtained in the same manner as above. The capsules thus obtained are filled with lactose powder,
The mating part of the body and cap is attached to the HPMC-AS above.
For those sealed with a 20% acetone solution,
When we observed the changes in the first solution (PH1.2), second solution (PH6.8) and tap water based on the 10th revision of the Japanese Pharmacopoeia, we obtained the results shown in the table below. .
【表】
実施例 2
実施例1のHPMC−ASを平均粒径15μとし、
この200gを水840gにかくはんしながら加え、よ
く分散させてから10%水酸化カリウム77gを徐々
に加えてHPMC−ASの水溶液を得た。この液を
40℃に保ち、これに別途調整した40℃の30%ゼラ
チン水溶液100gを添加し、3時間かくはんを続
け浸漬液とした。この浸漬液を40℃のまま保ち、
離型剤として流動パラフインを塗布したステンレ
ス製成型ピンを浸漬し、実施例1と同様にカプセ
ルを得た。
また別途、実施例1と同様に塩酸処理したカプ
セルおよび10%マレイン酸水溶液で3分間処理し
たカプセルを得、実施例1の方法にしたがいカプ
セルの試験を行つたところ、次の表に示すとおり
の結果が得られた。[Table] Example 2 The HPMC-AS of Example 1 had an average particle size of 15μ,
200 g of this was added to 840 g of water with stirring, and after being well dispersed, 77 g of 10% potassium hydroxide was gradually added to obtain an aqueous solution of HPMC-AS. This liquid
The temperature was maintained at 40° C., and 100 g of a 30% gelatin aqueous solution at 40° C., which had been prepared separately, was added thereto, and stirring was continued for 3 hours to obtain an immersion liquid. Keep this immersion liquid at 40℃,
Capsules were obtained in the same manner as in Example 1 by immersing a stainless steel molding pin coated with liquid paraffin as a mold release agent. Separately, capsules treated with hydrochloric acid and capsules treated with 10% maleic acid aqueous solution for 3 minutes in the same manner as in Example 1 were obtained, and the capsules were tested according to the method of Example 1. The results were obtained.
Claims (1)
ートサクシネートのアルカリ金属塩とゼラチンを
含む水溶液に成型ピンを浸漬し成型した後、酸水
溶液に浸漬処理することを特徴とする腸溶性カプ
セルの製造方法 2 ヒドロキシプロピルメチルセルロースアセテ
ートサクシネートを水に分散させ、かくはん下に
塩基およびゼラチンを加え溶解させて得た水溶液
を用いる特許請求の範囲第1項記載の腸溶性カプ
セルの製造方法 3 ヒドロキシプロピルメチルセルロースアセテ
ートサクシネートのアルカリ金属塩1重量部に対
するゼラチンの割合が0.05〜0.5重量部であるこ
とを特徴とする特許請求の範囲第1項記載の腸溶
性カプセルの製造方法 4 前記ヒドロキシプロピルメチルセルロースア
セテートサクシネートのアルカリ金属塩におい
て、アルカリ金属がヒドロキシプロピルメチルセ
ルロースアセテートサクシネートの酸性サクシノ
イル基に対して60%以上の当量であることを特徴
とする特許請求の範囲第1項記載の腸溶性カプセ
ルの製造方法。[Claims] 1. A method for producing enteric-coated capsules, which comprises immersing a molding pin in an aqueous solution containing gelatin and an alkali metal salt of hydroxypropyl methyl cellulose acetate succinate, molding the capsule, and then immersing the capsule in an acid aqueous solution. Method 3 for producing enteric-coated capsules according to claim 1 using an aqueous solution obtained by dispersing hydroxypropyl methylcellulose acetate succinate in water, adding and dissolving a base and gelatin while stirring Hydroxypropyl methylcellulose acetate succinate Method 4 for producing enteric capsules according to claim 1, characterized in that the ratio of gelatin to 1 part by weight of the alkali metal salt of hydroxypropyl methylcellulose acetate succinate is 0.05 to 0.5 parts by weight. 2. The method for producing enteric-coated capsules according to claim 1, wherein the amount of the alkali metal in the salt is 60% or more equivalent to the acidic succinoyl group of hydroxypropylmethylcellulose acetate succinate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026682A JPS58138458A (en) | 1982-02-10 | 1982-02-10 | Preparation of capsul dissolved in intestine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026682A JPS58138458A (en) | 1982-02-10 | 1982-02-10 | Preparation of capsul dissolved in intestine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58138458A JPS58138458A (en) | 1983-08-17 |
| JPH0347246B2 true JPH0347246B2 (en) | 1991-07-18 |
Family
ID=12022385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026682A Granted JPS58138458A (en) | 1982-02-10 | 1982-02-10 | Preparation of capsul dissolved in intestine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58138458A (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59193816A (en) * | 1983-04-19 | 1984-11-02 | Morishita Jintan Kk | Preparation of enteric soft capsule |
| JPH0634807B2 (en) * | 1989-06-08 | 1994-05-11 | 信越化学工業株式会社 | Method for manufacturing hard capsules for medicine |
| US5071706A (en) * | 1989-08-31 | 1991-12-10 | Eurand America, Incorporated | Oily, free-flowing, microcapsules |
| JP3449253B2 (en) * | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | Manufacturing method of hard capsule |
| CN1285333C (en) * | 2000-06-07 | 2006-11-22 | 张昊 | Colon-releasing oral preparation and its preparing method |
| US7790215B2 (en) * | 2002-03-26 | 2010-09-07 | Purdue Pharma Lp | Sustained-release gel coated compositions |
| EP2722104B1 (en) | 2010-10-26 | 2018-03-07 | Capsugel Belgium NV | Bulk Enteric Capsule Shells |
| CA2870134C (en) | 2012-05-02 | 2020-04-28 | Capsugel France SAS | Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas) |
| US20160256399A1 (en) | 2013-11-04 | 2016-09-08 | Capsugel Belgium Nv | Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole |
| US10471152B2 (en) | 2014-08-29 | 2019-11-12 | Capsugel Belgium Nv | Colloidal dispersion comprising HPMCAS |
| JP6683561B2 (en) | 2016-07-12 | 2020-04-22 | 信越化学工業株式会社 | Composition for enteric hard capsule and method for producing enteric hard capsule |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826666A (en) * | 1972-07-20 | 1974-07-30 | Parke Davis & Co | Enteric capsules |
| JPS607492B2 (en) * | 1979-04-28 | 1985-02-25 | 信越化学工業株式会社 | enteric-coated capsules |
-
1982
- 1982-02-10 JP JP2026682A patent/JPS58138458A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58138458A (en) | 1983-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4780898B2 (en) | Pectin film composition | |
| JP5666595B2 (en) | Aqueous composition for enteric hard capsule, method for producing enteric hard capsule, and enteric hard capsule | |
| CN102665697B (en) | Acid resistant capsules | |
| JPH0347246B2 (en) | ||
| US4547571A (en) | Process for preparing carboxymethyl ethyl cellulose suitable for enteric coating | |
| JPH08208458A (en) | Capsule film composition | |
| JPS6281402A (en) | Method for producing cellulose ether acidic dicarboxylic acid ester | |
| EP3178473B1 (en) | Acid resistant capsule shell and its preparation process | |
| WO1997017065A1 (en) | Cellulose acetate phthalate enteric coating compositions | |
| EP1221947A2 (en) | Soft gel capsule resistant to gastric juices | |
| JP2000202003A (en) | Hard capsule and method for producing the same | |
| JP6795587B2 (en) | Aqueous composition containing dispersed esterified cellulose ether | |
| JPH0561943B2 (en) | ||
| US3022287A (en) | Method of preparing cellulose esters of trimellitic acid | |
| JP5143024B2 (en) | Brown film composition and method for preparing the same | |
| JPH08245423A (en) | Water-based enteric coating liquid | |
| US4606771A (en) | Enteric coating liquid | |
| EP3090736B1 (en) | Aqueous composition for hard capsule, and hard capsule produced using same | |
| EP3556358B1 (en) | Acid resistant capsule shell composition | |
| JPH08269101A (en) | Method for dissolving carboxymethyl cellulose sodium salt | |
| JPS607492B2 (en) | enteric-coated capsules | |
| JPS647601B2 (en) | ||
| CN106138007A (en) | The constituent of preparation enteric capsule shells, enteric capsule shells and preparation method | |
| CN117257755A (en) | Quick-dissolving capsule shell material for enteric capsule and preparation method thereof | |
| JPH06157354A (en) | Enteric coating agent |